Zobrazeno 1 - 10
of 13
pro vyhledávání: '"K. D. Wilner"'
Autor:
Lawrence Herz, N Kletti, G N Ko, K D Wilner, Donald C. Goff, C G Law, J Simmons, K Lapierre, Thomas Posever
Publikováno v:
Journal of Clinical Psychopharmacology. 18:296-304
Ninety patients with schizophrenia or schizoaffective disorder according to DSM-III-R criteria participated in this double-blind, exploratory, dose-ranging trial. After a single-blind washout period of 4 to 7 days, patients were randomly assigned to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15bc4838be0b3a314639ed2506bfa1c7
https://doi.org/10.1097/00004714-199808000-00009
https://doi.org/10.1097/00004714-199808000-00009
Publikováno v:
Journal of the American Society of Nephrology. 6:242-247
Fluconazole (FLU) is a widely used antifungal agent. The multiple-dose pharmacokinetics of FLU in renal impairment have not been previously investigated. The following groups were studied: volunteers with creatinine clearances (CLcr, > 50 mL/min) of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ea076b30085052cf159ce1d81bb4fa7
https://doi.org/10.1681/asn.v62242
https://doi.org/10.1681/asn.v62242
Autor:
G, Everson, K C, Lasseter, K E, Anderson, L A, Bauer, R L, Carithens, K D, Wilner, A, Johnson, R J, Anziano, T A, Smolarek, R Z, Turncliff
Publikováno v:
British journal of clinical pharmacology. 49
To assess whether hepatic impairment influences the pharmacokinetics of ziprasidone.Thirty subjects with normal hepatic function or a primary diagnosis of clinically significant cirrhosis (Child-Pugh A or B) were enrolled into an open-label, multicen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a3d46296b6e0044b77b5327451ddd22e
https://pubmed.ncbi.nlm.nih.gov/10771450
https://pubmed.ncbi.nlm.nih.gov/10771450
Publikováno v:
British journal of clinical pharmacology. 49
To determine whether ziprasidone alters the metabolizing activity of the 2D6 isoenzyme of cytochrome P450 (CYP2D6).Twenty-four healthy young subjects aged 18-45 years were screened for CYP2D6 metabolizing activity and shown to be extensive metabolize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f98995674ae040d4ecff2855cf327f9b
https://pubmed.ncbi.nlm.nih.gov/10771453
https://pubmed.ncbi.nlm.nih.gov/10771453
Publikováno v:
Pharmacotherapy. 18(1)
To evaluate the influence of a high-fat meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic drug ziprasidone.Open, randomized, three-way crossover study.University-based research facility.Eight healthy male volunteer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::52d21601f4c2cc73f0fb7b457a61869b
https://pubmed.ncbi.nlm.nih.gov/9469675
https://pubmed.ncbi.nlm.nih.gov/9469675
Autor:
M G, Ziegler, K D, Wilner
Publikováno v:
The Journal of clinical psychiatry. 57
A double-blind, placebo-controlled, randomized, crossover study was conducted to determine the effect of sertraline on the beta-adrenergic blocking activity of atenolol in 10 healthy male volunteers.To assess the existence of any possible pharmacodyn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9aa4464ba37802402c787fd1f5523e8f
https://pubmed.ncbi.nlm.nih.gov/8617705
https://pubmed.ncbi.nlm.nih.gov/8617705
Publikováno v:
Journal of Clinical Oncology. 29:e13065-e13065
e13065 Background: Crizotinib is a selective, ATP-competitive, small molecule inhibitor of the ALK and MET/HGF receptor tyrosine kinases. Crizotinib is currently being developed as an orally admini...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f142468ad7778c3b95e6cf571cecafb
https://doi.org/10.1200/jco.2011.29.15_suppl.e13065
https://doi.org/10.1200/jco.2011.29.15_suppl.e13065
Autor:
A. Blasina, N. Brega, J. Gallo, A. N. Tse, S. G. Wong, C. Britten, K. D. Wilner, Grant A. McArthur, G. K. Schwartz, E. Wang
Publikováno v:
Journal of Clinical Oncology. 28:3062-3062
3062 Background: The S-phase and G2-checkpoints are critical mediators of the cell cycle response to cytotoxic therapy. PF-736 is a selective inhibitor of the S/G2-checkpoint kinase CHK1, displayin...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fcc7d8ac80dfe33a19c0ca096ca6584d
https://doi.org/10.1200/jco.2010.28.15_suppl.3062
https://doi.org/10.1200/jco.2010.28.15_suppl.3062
Autor:
K. Sekiguchi, J. Paulauskis, J. A. Williams, M. Man, K. D. Wilner, I. J. Jang, S. Myrand, X. Lin, R. Tzeng, C. Teng, Junichi Azuma, H. Kikkawa
Publikováno v:
Clinical Pharmacology & Therapeutics. 79:P82-P82
BACKGROUND/AIMS A key consideration for global drug development involves the acceptability of foreign clinical data. Inter-subject/inter-ethnic variability has been attributable to extrinsic and intrinsic factors. Clarifying this relationship by PK a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d88b7a531a7b68d80c0337cc61640c98
https://doi.org/10.1016/j.clpt.2005.12.295
https://doi.org/10.1016/j.clpt.2005.12.295
Publikováno v:
Clinical Neuropharmacology. 15:439B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e07ab29385d19b674d1d1f48ba2dbfe1
https://doi.org/10.1097/00002826-199202001-00854
https://doi.org/10.1097/00002826-199202001-00854